Erythropoietic growth factors for treatment-induced anemia in hepatitis C: A cost-effectiveness analysis

Clinical Gastroenterology and Hepatology

Volumn 3, Issue 10, 2005, Pages 1034-1042

  Spiegel, Brennan M R ^a,b,c   Chen, Kristina ^d   Chiou, Chiun Fang ^e   Robbins, Sean ^e   Younossi, Zobair M ^f  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Cerner Health Insights   (United States)

^e AMGEN INC   (United States)

^f INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; PEGINTERFERON; RIBAVIRIN;

ANEMIA; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; HEALTH CARE COST; HEPATITIS C; HUMAN; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; TREATMENT PLANNING;

ANEMIA; ANTIVIRAL AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; ERYTHROPOIETIN; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; RIBAVIRIN; TRANSAMINASES; TREATMENT OUTCOME;

EID: 26244451543     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(05)00695-6     Document Type: Article

References (51)

1. W.R. Kim, R.S. Brown, N.A. Tarrault Burden of liver disease in the United States summary of a workshop Hepatology 36 2002 227 242
2. M.P. Manns, J.G. McHutchison, S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial Lancet 358 2001 958 965
3. M.W. Fried, M.L. Shiffman, K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 34 2002 975 982
4. S.D. Sullivan, A. Crazi, A. Alberti Cost-effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C Pharmacoeconomics 22 2004 257 265
5. J.A. Salomon, M.C. Weinstein, J.K. Hammitt Cost-effectiveness of treatment for chronic hepatitis C in an evolving patient population JAMA 290 2003 228 237
6. M. Buti, M. Medina, M.A. Casado A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C Aliment Pharmacol Ther 17 2003 687 694
7. J.G. McHutchison, M. Manns, K. Patel Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
8. L. De Franceschi, G. Fattovich, F. Turrini Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection role of membrane oxidative damage Hepatology 31 2000 997 1004
9. M. Peck-Radosavljevic, M. Wichlas, M. Homoncik-Kraml Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha Gastroenterology 123 2002 141 151
10. PEG-Intron (peginterferon alfa-2b) package insert 2003 Schering Corporation Kenilworth, NJ
11. L.M. Martin, Z.M. Younossi, L. Price The impact of ribavirin-induced anemia on health-related quality of life Hepatology 34 Suppl 2001 600A
12. G.B. Gaeta, D.F. Precone, F.M. Felaco Premature discontinuation of interferon plus ribavirin for adverse effects a multicentre survey in 'real world' patients with chronic hepatitis C Aliment Pharmacol Ther 16 2002 1633 1639
13. D. Bernstein, L. Kleinman, C.M. Barker Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients Hepatology 35 2002 704 708
14. A.H. Talal, K. Weisz, T. Hau A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-α Am J Gastroenterol 96 2001 2802 2804
15. A.E. Gergely, P. Lafarge, I. Fouchard-Hubert Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C Hepatology 35 2002 1281 1282
16. N.H. Afdhal, D.T. Dieterich, P.J. Pockros Epoetin alfa maintains ribavirin dose in HCV-infected patients a prospective, double-blind, randomized controlled study Gastroenterology 126 2004 1302 1311
17. D.T. Dieterich, R. Wasserman, N. Brau Once-weekly epoietin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa Am J Gastroenterol 98 2003 2491 2499
18. L.E. Senkbeil, J.G. Moss, P. Gaglio Erythropoietin maintains ribavirin dose and sustained virologic response during HCV treatment (abstr) Hepatology 38 Suppl 1 2003 744A
19. Z.M. Younossi, J.P. Ong, R. Collantes Darbepoetin alfa for ribavirin-induced anemia in patients with chronic hepatitis C treated with pegylated interferon and ribavirin a preliminary analysis (abstr) Gastroenterology 126 Suppl 2 2004 A83
20. P.J. Pockros, M.L. Shiffman, E.R. Schiff Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 2004 1450 1458
21. M.F. Drummond, W.S. Richardson, B.J. O'Brien Evidence-Based Medicine Working Group Users' guide to the medical literature XIII. How to use an article on economic analysis of clinical practice JAMA 277 1997 1552 1557
22. D.T. Lau, D.E. Kleiner, M.G. Ghany 10-year follow-up after interferon-alpha therapy for chronic hepatitis C Hepatology 28 1998 1121 1127
23. J.G. McHutchison, S.C. Gordon, E.R. Schiff Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1998 1485 1492
24. T. Poynard, P. Marcellin, S.S. Lee International Hepatitis Interventional Therapy Group (IHIT) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1426 1432
25. K. Lindsay, C. Trepo, T. Heintges A randomized double-blind trial comparing pegylated interferon to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 2001 395 403
26. J. Heathcote, M. Schiffmann, G. Cooksley Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 2000 1673 1680
27. Center for Disease Control. National Center for Health Statistics. National Vital Statistics Report. Available at: http://www.cdc.gov/nchs/. Accessed: May, 2004.
28. M.R. Gold J.E. Siegel L.B. Russell Cost-effectiveness in health and medicine 1996 Oxford University Press New York, NY
29. C.A. Chong, A. Gulamhussein, E.J. Heathcote Health-state utilities and quality of life in hepatitis C patients Am J Gastroenterol 98 2003 630 638
30. H.R. Peeters, M. Jongen-Lavrencic, C.H. Bakker Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures Rheumatol Int 18 1999 201 206
31. M.S. Sulkowski, R. Wasserman, L.J. Brooks Changes in hemoglobin during therapy with interferon alfa-2b plus ribavirin in IFN-naive and experienced patients (abstr) Hepatology 32 2000 368A
32. D.G. Fryback, W.F. Lawrence, P.A. Martin Predicting quality of well-being scores from the SF-36 results from the Beaver Dam Health Outcomes Study Med Decis Making 17 1997 1 9
33. United States Department of Labor Bureau of Labor Statistics. Consumer price index calculator. Available at: www.bls.gov. Accessed: April 2005.
34. P. Muennig Designing and conducting cost-effectiveness analyses in medicine and health care 2002 Jossey-Bass San Francisco
35. T. Poynard, P. Marcellin, S.S. Lee International Hepatitis Interventional Therapy Group (IHIT) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1426 1432
36. T. Poynard, P. Bedossa, P. Opolon OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups Natural history of liver fibrosis progression in patients with chronic hepatitis C Lancet 349 1997 825 832
37. National Institutes of Health Consensus Development Conference Management of hepatitis C Hepatology 26 Suppl 1 1997 1S 156S
38. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study N Engl J Med 319 1988 983 989
39. G.J. Gores, R.H. Weisner, E.R. Dickson Prospective evaluation of esophageal varices in primary biliary cirrhosis development, natural history and influence in survival Gastroenterology 96 1989 1552 1559
40. U. Siebert, G. Sroczynski, S. Rossol German Hepatitis C Model (GEHMO) Group, International Hepatitis Interventional Therapy (IHIT) group Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b ribavirin for initial treatment of chronic hepatitis C Gut 52 2003 425 432
41. G. Fattovich, G. Giustina, F. Degos Morbidity and mortality in compensated cirrhosis type C a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
42. F. Salerno, G. Borroni, P. Moser Survival and prognostic factors of cirrhotic patients with ascites a study of 134 outpatients Am J Gastroenterol 88 1993 514 519
43. United Network of Organ Sharing. Available at: www.unos.org. Accessed: June 2004.
44. 2002 red book of average wholesale drug prices 2002 Thompson Medical Economics Montvale, NJ
45. American Medical Association AMA CPT code book 2004
46. T.A. Lieu, R.J. Gurley, R.J. Lundstrom Projected cost-effectiveness of primary angioplasty for acute myocardial infarction J Am Coll Cardiol 30 1997 1741 1750
47. R.D. Moore, R.E. Chiasson Cost-utility analysis of prophylactic treatment with gancyclovir for cytomegalovirus retinitis J Acquir Immune Defic Syndr Hum Retrovirol 16 1997 15 21
48. B.M. Spiegel, L.E. Targownik, G.S. Dulai The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis Ann Intern Med 138 2003 795 806
49. J.B. Wong, W.G. Bennett, R.S. Koff Pretreatment evaluation of chronic hepatitis C risks, benefits, and costs JAMA 280 1998 2088 2093
50. B.M. Spiegel, Z.M. Younossi, R.D. Hays The impact of hepatitis C on health related quality of life a systematic review of the literature Hepatology 41 2005 790 800
51. G.L. Davis, J.B. Wong, J.G. McHutchison Early virological response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 653